Azeloprazole

Azeloprazole

SCHEMBL711093

Cc1cnc(C[S+]([O-])c2nc3ccccc3[nH]2)c(C)c1OCC1COC(C)(C)OC1.[NaH]

nearest known ligand 0.40

Full drug profile on Sugi Atlas →

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
WDR5 P61964 1/20 0.40
KMT2A Q03164 1/20 0.40
SARM1 Q6SZW1 1/20 0.39
ATP4A P20648 1/20 0.33
ATP4B P51164 1/20 0.33
NPC1 O15118 2/20 0.32
RAB9A P51151 2/20 0.32
SMN1; SMN2 Q16637 1/20 0.31
BRS3 P32247 1/20 0.30
AR P10275 1/20 0.30
APP P05067 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Azeloprazole SCHEMBL4338561 1.00 WDR5 (0.40) WDR5KMT2ASARM1ATP4AATP4B
Azeloprazole SCHEMBL4336045 1.00 WDR5 (0.40) WDR5KMT2ASARM1ATP4AATP4B
Azeloprazole SCHEMBL4333430 0.99 KMT2A (0.40) WDR5KMT2ASARM1ATP4AATP4B
Azeloprazole SCHEMBL4333414 0.99 KMT2A (0.40) WDR5KMT2ASARM1ATP4AATP4B
Azeloprazole SCHEMBL710150 0.99 KMT2A (0.40) WDR5KMT2ASARM1ATP4AATP4B
Azeloprazole SCHEMBL31312701 0.99 KMT2A (0.40) WDR5KMT2ASARM1ATP4AATP4B
Azeloprazole SCHEMBL4492343 0.98 WDR5 (0.40) WDR5KMT2ASARM1ATP4AATP4B
Azeloprazole SCHEMBL4338563 0.98 WDR5 (0.40) WDR5KMT2ASARM1ATP4AATP4B
Azeloprazole SCHEMBL711094 0.98 WDR5 (0.40) WDR5KMT2ASARM1ATP4AATP4B
Azeloprazole SCHEMBL4336050 0.98 WDR5 (0.40) WDR5KMT2ASARM1ATP4AATP4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090182149-A1 SALT OF SULFINYLBENZIMIDAZOLE COMPOUND, AND CRYSTAL AND AMORPHOUS FORM THEREOF EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-07-16 US claimed
EP-2077265-A1 SALT OF SULFINYLBENZIMIDAZOLE COMPOUND, AND CRYSTAL AND AMORPHOUS FORM THEREOF Eisai R&D Management Co., Ltd. (JP) 2009-07-08 EP claimed
US-9040564-B2 Stabilized composition EISAI R&D MANAGEMENT CO., LTD. (JP) 2015-05-26 US disclosed
US-8124780-B2 Benzimidazole compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2012-02-28 US disclosed
EP-1870409-B1 BENZIMIDAZOLE COMPOUNDS EISAI R&D MAN CO LTD (JP) 2010-05-12 EP disclosed
US-20090274756-A1 Stabilized composition EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-11-05 US disclosed
US-20090203911-A1 BENZIMIDAZOLE COMPOUND MIYAZAWA SHUHEI 2009-08-13 US disclosed
US-20090182149-A1 SALT OF SULFINYLBENZIMIDAZOLE COMPOUND, AND CRYSTAL AND AMORPHOUS FORM THEREOF EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-07-16 US disclosed
EP-2077265-A1 SALT OF SULFINYLBENZIMIDAZOLE COMPOUND, AND CRYSTAL AND AMORPHOUS FORM THEREOF Eisai R&D Management Co., Ltd. (JP) 2009-07-08 EP disclosed
US-7425634-B2 Benzimidazole compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-09-16 US disclosed
US-20080145421-A1 A layer of a benzamidazole-proton pump inhibitor and ethyl celluose is coated on an inert or basic material core material; an exterior layer of enteric polymer to prevent the dissolution of the drug in the stomach but in the intestines; storage stability; time-release agents; gastrointestinal disorders EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-06-19 US disclosed
EP-1875911-A1 STABILIZED COMPOSITION Eisai R&D Management Co., Ltd. (JP) 2008-01-09 EP disclosed
EP-1870409-A1 BENZIMIDAZOLE COMPOUND Eisai R&D Management Co., Ltd. (JP) 2007-12-26 EP disclosed
US-20070015782-A1 Benzimidazole compound EISAI CO., LTD. 2007-01-18 US disclosed
US-20070010542-A1 Benzimidazole compound EISAI CO., LTD. 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090182149-A1 SALT OF SULFINYLBENZIMIDAZOLE COMPOUND, AND CRYSTAL AND AMORPHOUS FORM THEREOF BRI3BP, SNRK, SRI WDR5 1543/4885KMT2A 500/4885SARM1 3558/4885
US-20080145421-A1 A layer of a benzamidazole-proton pump inhibitor and ethyl celluose is coated on an inert or basic material core material; an exterior layer of enteric polymer to prevent the dissolution of the drug in the stomach but in the intestines; storage stability; time-release agents; gastrointestinal disorders SI, CEL, PGA5 WDR5 3817/4885KMT2A 3022/4885SARM1 4854/4885
US-20090274756-A1 Stabilized composition SI, PGA5, CEL WDR5 3071/4885KMT2A 4419/4885SARM1 4820/4885
US-20070010542-A1 Benzimidazole compound HRH2, GIPR, HRH4 WDR5 793/4885KMT2A 4213/4885SARM1 4535/4885
US-20090203911-A1 BENZIMIDAZOLE COMPOUND HRH2, HRH4, HRH1 WDR5 950/4885KMT2A 3821/4885SARM1 4611/4885
US-20070015782-A1 Benzimidazole compound HRH2, GIPR, HRH4 WDR5 793/4885KMT2A 4213/4885SARM1 4535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.